Coppieters Ken, von Herrath Matthias
Novo Nordisk (Denmark), Copenhagen, Denmark.
Front Med (Lausanne). 2018 Oct 9;5:283. doi: 10.3389/fmed.2018.00283. eCollection 2018.
Optimized insulin therapies, increased use of continuous glucose monitoring/insulin pumps and most importantly the arrival of reliable closed loop systems will undeniably lead to a reduction in the burden of complications that arise from type 1 diabetes. However, insulin therapy will only ever treat the symptoms of the disease and will not alter the underlying pathology. The aim of immunotherapy treatment is to modulate the immune system, a strategy that has been successful in autoimmune conditions such as multiple sclerosis, rheumatoid arthritis and lupus. However, the success rate of immunotherapy treatment in type 1 diabetes has been low. There are several distinct stages of T1D development. In this review, we summarize the most important immunotherapeutic approaches tested thus far and focus on the characteristic features and unmet need within the different stages of the disease.
优化的胰岛素疗法、持续葡萄糖监测/胰岛素泵的更多使用，以及最重要的是可靠的闭环系统的出现，无疑将减轻1型糖尿病引发的并发症负担。然而，胰岛素疗法永远只能治疗疾病的症状，而不会改变潜在的病理状况。免疫疗法的目的是调节免疫系统，这一策略在诸如多发性硬化症、类风湿性关节炎和狼疮等自身免疫性疾病中已取得成功。然而，免疫疗法在1型糖尿病中的成功率一直很低。1型糖尿病的发展有几个不同阶段。在本综述中，我们总结了迄今为止测试的最重要的免疫治疗方法，并关注疾病不同阶段的特征和未满足的需求。
